Investigative report on Chinese daratumumab markets, 2016-2020 and 2021-2025: Developed by Johnson & Johnson – A monoclonal antibody available for the treatment of myeloma


DUBLIN, March 07, 2022–(BUSINESS WIRE)–The “China Daratumumab Market Investigation Report 2021-2025” report has been added to from offer.

Daratumumab, developed by Johnson & Johnson, is a monoclonal antibody available for the treatment of myeloma. Its DARZALEX product has been approved for the treatment of patients with multiple myeloma who have received at least one therapy, including a proteasome inhibitor and an immunomodulatory agent.

It is the first anti-human CD38 monoclonal antibody (mAb) approved worldwide. Daratumumab was approved in China in 2019 and, as of the first half of 2021, Janssen-Cilag International NV(BE) is the only manufacturer in the Chinese market for daratumumab.

According to the market researcher, since daratumumab entered the Chinese market in 2019, its sales have increased rapidly. Sales of Daratumumab increased from about CNY 0.5 million in 2019 to about CNY 24.82 million in 2020, with an annual increase of more than 40 times.

The analyst predicts that its sales volume will continue to grow from 2021 to 2025 with the expansion of the daratumumab market. In 2020, Johnson & Johnson filed two applications for approval of Daratumumab in China for new indications. With the increase in the number of indications, its sales volume will continue to grow.

In addition, daratumumab, a new human monoclonal antibody, binding to CD38, is more effective than bortezomib and lenalidomide. Therefore, Daratumumab’s market share will increase and sales will continue to increase in the future.

Topics Covered:

  • The impact of COVID-19 on the Chinese daratumumab market

  • Chinese Daratumumab Sales Value 2016-2020

  • Competitive Landscape of China Daratumumab Market

  • Daratumumab price in China

  • Daratumumab Price in China by Regions and Manufacturers

  • Analysis of factors affecting the development of the Chinese daratumumab market

  • China Daratumumab Market Outlook 2021 to 2025

Main topics covered:

1 Relevant Concepts of Daratumumab

1.1 Indications for daratumumab

1.2 Development of Daratumumab in China

1.3 Government approval of daratumumab in China

1.4 The impact of COVID-19 on Daratumumab sales in China

2 China Daratumumab Sales, 2018-2020

2.1 Daratumumab Sales Value

2.1.1 Overall sales value

2.1.2 Sales Value by Region

2.2 Daratumumab Sales Volume

2.2.1 Overall Sales Volume

2.2.2 Sales Volume by Region

2.3 China Daratumumab Sales by Dosage Form, 2018-2020

2.3.1 Injection

2.3.2 Analysis of other dosage forms

3 Analysis of Daratumumab Key Manufacturers in China, 2018-2020

3.1 Daratumumab Major Manufacturers Market Share Analysis

3.1.1 Market Share Survey by Sales Value

3.1.2 Market Share Survey by Sales Volume

3.2 Janssen-Cilag International SA(BE)

3.2.1 Company profile

3.2.2 DARZALEX (Daratumumab by Janssen-Cilag International NV(BE)) Sales in China

4 Daratumumab Price for Different Manufacturers in China, 2020-2021

4.1 Janssen-Cilag International NV(BE) (DARZALEX)

4.2 Analysis of other companies

5 China Daratumumab Drug Market Outlook, 2021-2025

5.1 Influencing Factors of China Daratumumab Market Development

5.1.1 The impact of COVID-19 on the Chinese daratumumab market

5.1.2 Market Drivers and Opportunities

5.1.3 Market Threats and Challenges

5.2 Market Size Forecast

5.3 Market Trend Forecast

For more information on this report, visit

See the source version on

Laura Wood, Senior Press Officer
[email protected]

For EST business hours, call 1-917-300-0470
For US/CAN call toll free 1-800-526-8630
For GMT office hours call +353-1-416-8900


Comments are closed.